Phase 3 Chronic Kidney Disease Trial, Recruiting NCT05510323 Sponsor: Air Force Military Medical University, China Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT05510323
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with IgA nephropathy (a kidney disease) confirmed by a biopsy (a small tissue sample taken from the kidney).
  • People who have a significant amount of protein leaking into their urine (at least 1.0g per day) even while taking the highest tolerable dose of blood pressure or kidney-protective medication.
  • People whose kidneys are working at a reduced but not critically low level, within a specific range measured by a kidney function test (confirm with trial site for exact values).

Who may not be able to join:

  • People who either need to take, or cannot safely take, steroid-based immune-suppressing medications.
  • People who have taken steroids or other immune-suppressing drugs at any point in the past year.
  • People whose kidney function is currently unstable for reasons other than IgA nephropathy.
  • People who are under 18 years of age.
  • People whose IgA nephropathy was caused by another underlying condition (known as secondary IgA nephropathy).
  • People whose treating doctor does not think they would be able to follow the study requirements consistently.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Air Force Military Medical University, China
Registry
ClinicalTrials.gov
Start date
1 February 2024
Est. completion
1 August 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Combined event

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov